Mirae Asset Mutual Fund · #154169 · stale / inactive
Mirae Asset Nifty 500 Healthcare ETF
Exchange Traded Funds (ETFs) · Equity ETF · Regular · IDCW
Regular TER: 0.35% · as of
5-year NAV · change the window using the controls in the rolling-returns card below ↓
2026-02-11 → 2026-10-22
Latest NAV
₹20.1539
as of 2026-10-22 · +0.03% vs 2026-10-21
Earliest NAV in archive
2026-02-11
AMFI archive begins Apr 2006
Trailing CAGR vs assigned benchmark
insufficient data
Monthly returns · since inception (Feb 2026)
How each calendar month went: green months gained, red months lost. Deeper colour = bigger move.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | · | · | -5.2 | +6.3 | +4.8 | +5.2 | +3.4 | +1.5 | -3.8 | -4.7 | · | · | +6.9 |
| Avg | · | · | -5.2 | +6.3 | +4.8 | +5.2 | +3.4 | +1.5 | -3.8 | · | · | · | · |
All values in %. Each cell compares the last NAV of the month with the last NAV of the month before. The latest month is month-to-date; the Year column compounds the months shown on that row.
Portfolio mix · asset class breakdown as of 2026-09-30
Size axis (Style Box) · Large / Mid / Small split of latest disclosed holdings
Per AMFI's semi-annual Categorisation of Stocks (top 100 = Large, 101-250 = Mid, 251+ = Small).
- Large Cap 36.0%
- Mid Cap 45.7%
- Small Cap 18.3%
Index overlap
· vs · share of this fund's AUM that sits in stocks the index also includes32.7%
5 of 44 holdings are index members
Mostly stocks outside the benchmark universe
As of 2026-09-30
How to read this: This number shows whether the fund invests in the same stocks as the index. It does not show whether the fund weights those stocks like the index. A low number (say below 60%) means the fund holds a meaningful share in stocks the index doesn't carry at all (typical of sectoral, small-cap-tilted or international funds vs a broad benchmark). A high number (80%+) is normal for any large-cap or flexi-cap fund, because Indian active funds mostly pick from the same large and mid-cap stocks as the Nifty 500. It does not on its own signal a closet index fund; to identify that you'd need per-stock weight comparison, which requires index constituent weights we don't currently ingest.
Top stocks held · 44 holdings as of 2026-09-30 See changes vs previous snapshot →
| Stock | Sector | % of fund |
|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Pharmaceuticals & Biotechnology | 10.13% |
| Divi's Laboratories Ltd. | Pharmaceuticals & Biotechnology | 8.76% |
| Apollo Hospitals Enterprise Ltd. | Healthcare Services | 6.24% |
| Laurus Labs Ltd. | Pharmaceuticals & Biotechnology | 5.72% |
| Cipla Ltd. | Pharmaceuticals & Biotechnology | 5.62% |
| Dr. Reddy's Laboratories Ltd. | Pharmaceuticals & Biotechnology | 5.58% |
| Torrent Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | 5.24% |
| Max Healthcare Institute Ltd. | Healthcare Services | 5.13% |
| Lupin Ltd. | Pharmaceuticals & Biotechnology | 3.66% |
| Aurobindo Pharma Ltd. | Pharmaceuticals & Biotechnology | 3.43% |
| Fortis Healthcare Ltd. | Healthcare Services | 2.98% |
| Glenmark Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | 2.61% |
| Alkem Laboratories Ltd. | Pharmaceuticals & Biotechnology | 2.31% |
| Zydus Lifesciences Ltd. | Pharmaceuticals & Biotechnology | 2.13% |
| Mankind Pharma Ltd. | Pharmaceuticals & Biotechnology | 2.10% |
| IPCA Laboratories Ltd. | Pharmaceuticals & Biotechnology | 1.99% |
| Biocon Ltd. | Pharmaceuticals & Biotechnology | 1.91% |
| Gland Pharma Ltd. | Pharmaceuticals & Biotechnology | 1.71% |
| Sai Life Sciences Ltd. | Pharmaceuticals & Biotechnology | 1.56% |
| Krishna Institute of Medical Sciences Ltd. | Healthcare Services | 1.48% |
Sector mix
- Healthcare 100.0%
Risk metrics, trailing 3y (93 matched daily returns, 2026-02-12 → 2026-07-02)
Calmar
—
CAGR / |max DD| in window
Risk-free rate assumed 6.0% annualised. Benchmark = Nifty 50 TRI (assigned by category mapping).
Factual data only. No investment advice or recommendation. Read the scheme document and consult a SEBI-registered Investment Adviser for personalised guidance.